Eichenfield Lawrence F, Friedlander Sheila Fallon
J Drugs Dermatol. 2017 Feb 1;16(2):105-109.
Fungal infection of the nails is an increasingly recognized disease in infants and children. However, it can be difficult to distinguish clinically from other nail dystrophies. In addition, many mistakenly believe that onychomycosis does not occur in childhood. Under-recognition of this infectious disorder therefore occurs. Although many consider "nail fungus" a trivial cosmetic concern, it can lead to discomfort, risk of secondary infection, and a more significant health threat in immunocompromised or diabetic individuals. It should always be considered in the differential diagnosis of nail plate disorders in children as it is one of the more common causes.
Here we review the latest data on prevalence of the disease, reasons for its relatively low incidence compared with adults, and important predisposing factors. It is important to confirm the clinical diagnosis of onychomycosis in children, and affected individuals should be examined for concomitant tinea pedis. As familial disease often occurs, it is important to check parents and siblings as well for onychomycosis and tinea pedis.
Treatment of onychomycosis is challenging, and recurrence appears to be more common in children than in adults. Prolonged systemic antifungal therapy is commonly required. However, pediatric practitioners and parents alike hesitate when asked to treat young children with a systemic drug that requires laboratory monitoring and can have systemic toxicities. Due to their thinner, faster-growing nails, children are theoretically more likely to respond to topical monotherapy than adults, and therefore good candidates for topical antifungal therapy.
The clinical data on the use of topical antifungals in pediatric onychomycosis is scarce. We review data that exist from case reports and small clinical trials. New topical antifungals are now available that afford better nail penetration and additional delivery routes to the site of infection. Pediatric trials are now on-going, and should clarify the usefulness of these agents in children.
指甲真菌感染在婴幼儿和儿童中是一种日益被认识到的疾病。然而,临床上很难将其与其他指甲营养不良区分开来。此外,许多人错误地认为甲癣不会发生在儿童期。因此,这种感染性疾病未得到充分认识。尽管许多人认为“指甲真菌”只是一个微不足道的美容问题,但它可能导致不适、继发感染风险,并且在免疫功能低下或糖尿病个体中会构成更严重的健康威胁。在儿童指甲板疾病的鉴别诊断中应始终考虑到它,因为它是较常见的病因之一。
在此,我们回顾了关于该疾病患病率、与成人相比发病率相对较低的原因以及重要易感因素的最新数据。确认儿童甲癣的临床诊断很重要,应对受影响个体检查是否伴有足癣。由于常出现家族性疾病,检查父母和兄弟姐妹是否患有甲癣和足癣也很重要。
甲癣的治疗具有挑战性,复发在儿童中似乎比在成人中更常见。通常需要长期的全身抗真菌治疗。然而,当被要求用一种需要实验室监测且可能有全身毒性的全身性药物治疗幼儿时,儿科医生和家长都会犹豫不决。由于儿童的指甲更薄、生长更快,理论上他们比成人更有可能对局部单一疗法产生反应,因此是局部抗真菌治疗的理想人选。
关于局部抗真菌药用于儿童甲癣的临床数据很少。我们回顾了病例报告和小型临床试验中的现有数据。现在有了新的局部抗真菌药,它们能更好地穿透指甲并提供额外的感染部位给药途径。儿科试验正在进行中,应该会阐明这些药物在儿童中的有效性。